# Bayesian Prediction of Severe Outcomes in the LabMarCS: Laboratory Markers of COVID-19 Severity - Bristol Cohort

Brian Sullivan<sup>a,\*</sup>, Edward Barker<sup>a</sup>, Philip Williams<sup>c</sup>, Louis MacGregor<sup>a</sup>, Ranjeet Bhamber<sup>a</sup>, Matt Thomas<sup>b</sup>, Stefan Gurney<sup>c</sup>, Catherine Hyams<sup>a,b</sup>, Alastair Whiteway<sup>b</sup>, Jennifer A Cooper<sup>a</sup>, Chris McWilliams<sup>a</sup>, Katy Turner<sup>a</sup>, Andrew W. Dowsey<sup>a</sup>, Mahableshwar Alburb

#### **Abstract**

**Objectives:** To develop cross-validated prediction models for severe outcomes in COVID-19 using blood biomarker and demographic data; Demonstrate best practices for clinical data curation and statistical modelling decisions, with an emphasis on Bayesian

**Design:** Retrospective observational cohort study.

Setting: Multicentre across National Health Service (NHS) trusts in Southwest region, England, UK.

Participants: Hospitalised adult patients with a positive SARS-CoV 2 by PCR during the first wave (March – October 2020). 843 COVID-19 patients (mean age 71, 45% female, 32% died or needed ICU stay) split into training (n=590) and validation groups (n=253) along with observations on demographics, co-infections, and 30 laboratory blood biomarkers.

Primary outcome measures: ICU admission or death within 28-days of admission to hospital for COVID-19 or a positive PCR result if already admitted.

Results: Predictive regression models were fit to predict primary outcomes using demographic data and initial results from biomarker tests collected within 3 days of admission or testing positive if already admitted. Using all variables, a standard logistic regression yielded an internal validation median AUC of 0.7 (95% Interval [0.64,0.81]), and an external validation AUC of 0.67 [0.61, 0.71], a Bayesian logistic regression using a horseshoe prior yielded an internal validation median AUC of 0.78 [0.71, 0.85], and an external validation median AUC of 0.70 [0.68, 0.71]. Variable selection performed using Bayesian predictive projection determined a four variable model using Age, Urea, Prothrombin time and Neutrophil-Lymphocyte ratio, with a median AUC of 0.74 [0.67, 0.82], and external validation AUC of 0.70 [0.69, 0.71].

Conclusions: Our study reiterates the predictive value of previously identified biomarkers for COVID-19 severity assessment. Given the small data set, the full and reduced models have decent performance, but would require improved external validation for clinical application. The study highlights a variety of challenges present in complex medical data sets while maintaining best statistical practices with an emphasis on showcasing recent Bayesian methods.

#### Introduction

Globally, as of 14 July 2022, there have been 556 million 16 confirmed cases of COVID-19, including 6.35 million deaths, 17 with 23.1 million cases in the UK, resulting in over 181,000 18 deaths (WHO Coronavirus (COVID-19) Dashboard, https: 19 //covid19.who.int/). COVID-19 has a wide spectrum of 20 clinical features ranging from asymptomatic to severe systemic 21 illness with a significant attributable mortality, while clinical 22 manifestations are variable especially in the most vulnerable 23 groups and immunocompromised people [1]. COVID-19 is a 24 multi-system disease resulting in the derangements of homeostasis affecting pulmonary, cardiovascular, coagulation, haema-26 tological, oxygenation, hepatic, renal and fluid balance [2, 3, 4, 27]

5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. Although the majority of people with COVID-19 will have mild or no symptoms, a small but significant proportion will suffer from a severe infection needing hospitalisation for supportive care, oxygen, or admission to intensive care units(ICU) for respiratory support.

Early identification of hospitalised COVID-19 patients who are likely to deteriorate, i.e. transfer to ICU or who may die, is vital for clinical decision making. Healthcare systems across the world including highly developed countries continue to face challenges in terms of capacity and resources to manage this pandemic, as lock down measures have been relaxed, including opening of schools and businesses.

Published prediction models to date have evaluated case level factors that might predict poor outcomes (critical illness or death). A recent living systematic review [17] identified 265 prognostic models for mortality and 84 for progression to se-Email addresses: brian.sullivan@bristol.ac.uk (Brian Sullivan), 30 vere or critical state. The majority of the studies looked at vital mahablesh NOTE This or print space that has not been certified by peer review and should not be used to guide clinical practice.

<sup>&</sup>lt;sup>a</sup>University Of Bristol

<sup>&</sup>lt;sup>b</sup>Southmead Hospital, North Bristol NHS Trust

<sup>&</sup>lt;sup>c</sup>University Hospitals Bristol and Weston NHS Trust

<sup>\*</sup>Corresponding Authors

signs, age, comorbidities, and radiological features. Models were unlikely to include a broad range of variables concerning co-infection, biochemical factors (outside of C-reactive protein), and other haematological factors on an individual patient level. Most of the prognostic models did not describe the target population or care setting adequately, did not fully describe the regression equation, showed high or unclear risk of bias and/or were inadequately evaluated for performance.

# Goals

33

34

36

37

40

43

44

45

54

55

60

61

72

73

75

78

The present study analyzes a range of laboratory blood marker values across metabolic pathways affected by COVID-19 infection (i.e. a core set of biomarkers feasible for clinical collection) and evaluates predictive models of severe outcomes. The main objectives of the study are: (1) Examine statistical associations of routinely measured physiological and blood biomarkers, and age and gender, to predict severe COVID-19 outcomes. (2) Develop cross-validated logistic regression prediction models using the best candidate biomarkers, and highlight biomarkers worthy of future research. (3) Use variable selection techniques including least absolute shrinkage and selection operator (LASSO) regularisation [18] and Bayesian Projective Prediction [19] to illustrate the process of creating a reduced model that maintains reasonable performance and is more feasible to use clinically (4) In each of these steps demonstrate best analytic practices for explaining clinical data curation and statistical modelling decisions, with an emphasis on showcasing the capabilities of recent Bayesian methods.

# Methods

# Study Cohort and Demographics

Pseudonymised data was obtained from laboratory information management system (LIMS) linking patient data for laboratory markers to key clinical outcomes. Three hospitals in the Southwest region of England, UK, participated in the study, two of them were tertiary teaching hospitals and the third was a district general hospital (DGH). A system wide data search was conducted on LIMS for all patients who tested positive for SARS-CoV-2 by polymerase chain reaction (PCR) at these three hospitals during the first wave of COVID-19 pandemic (01/03/2020 to 31/10/2020). The serial pathology data collected as a part of standard of care of patients admitted with/for COVID-19 were included- bacteriology, virology, mycology, haematology, and biochemistry. All patients testing negative for SARS CoV 2 by PCR were excluded. All laboratory markers including clinical outcomes from LIMS were extracted and the final dataset was anonymized with no patient identifying data to link back.

# Inclusion and exclusion criteria

We included all adult patients admitted to study hospitals and tested positive for SARSCoV-2 by PCR. Pediatric patients (<18 years old) and staff/healthcare workers and their household contacts were excluded. Figure 1 depicts the decision flow for inclusion and exclusion of patient data.




Figure 1: Flowchart of patient exclusion and inclusion criteria. The initial set of 1159 candidate patients was narrowed to a training set (n=590) and a validation set (n=253).

#### Data Covariates

The LabMarCS dataset includes a variety of host, clinical <sup>132</sup> severity indices, microbiological, immunological, haematolog-<sup>133</sup> ical and biochemistry parameters used as predictive variables <sup>134</sup> in the regression models. A full list of recorded data items is <sup>135</sup> shown in Figure 2

#### Outcomes

For all sites, the primary prediction outcome was death or <sup>139</sup> transfer to the ICU within 28 days of admission to hospital, <sup>140</sup> or the first positive COVID-19 PCR test result if already admit-<sup>141</sup> ted. This generally corresponds to WHO-COVID-19 Outcomes <sup>142</sup> Scale Score 6–10 (severe) versus 0–5 (mild/moderate) [20].

#### Patient Timelines

The collected laboratory biomarkers are continuous measures and provide a time series representation of the course of a<sub>147</sub> patient's admission. Figure 3 shows an example of a single pa-<sub>148</sub> tient's readings over the course of 18 days between testing pos-<sub>149</sub> itive for COVID-19 and being released from hospital care. This provides a representative example of the heterogeneity seen in our dataset, i.e. not all tests are taken and others are taken regu-<sub>152</sub> larly or intermittently (further examples in Supplementary Fig-<sub>153</sub> ures S2 - S6).

#### Transformation of Biomarker Data

Prediction modelling of irregularly sampled time-series data<sub>157</sub> is a challenging open research question [21]. In this study we<sub>158</sub> focused on established and available tools for conventional and<sub>159</sub> Bayesian prediction. To balance inclusion of test data not avail-<sub>160</sub> able on the day of admission and the need for clinical decisions to be guided soon after admission, we chose to consider<sup>161</sup> the first value recorded for each biomarkers within three days<sub>162</sub> of their 'critical date'. In addition, we transformed continuous<sub>163</sub> biomarkers into categorical variables via reference ranges for<sub>164</sub> clinical use in the typical healthy population ranges, see Fig-<sub>165</sub> ure 2. As an example, Figure 4 shows the histogram of read-<sub>166</sub> ings for all values recorded for Neutrophils, including clinical<sub>167</sub> thresholds to transform into categorical data. No missing data<sub>168</sub> imputation was performed, instead missingness was coded as<sub>169</sub> as an additional category 'Test not taken'.

For further elaboration on the challenges of these modelling 171 choices, please see Discussion Sectionc.

#### Statistical Analysis

Analytics were carried out using the R statistical language<sup>176</sup> (v4.13) and R Studio (Prairie Trillium release). We used the<sup>177</sup> following packages: Standard logistic regression analyses used<sup>178</sup> the R Stats GLM package (v3.6.2); LASSO analyses, GLMnet<sup>179</sup> (v4.1-4); and for Bayesian analyses, BRMS (v2.17) and Pro-<sup>180</sup> jPred (v2.1.2). Source code for this analysis pipeline can be<sup>181</sup> found at https://github.com/biospi/LABMARCS.

### Analysis of Individual Biomarkers

Before running full regression models we examined the independent contribution of individual biomarkers in predicting ICU entry or death via standard logistic regressions and Bayesian logistic regressions with either a flat (aka uniform) or horseshoe prior. This allowed calculation of p-values and odds ratios for each biomarker. A 5-fold cross-validation repeated 20 times was run for each biomarker to estimate the median AUC and 95% interquartile intervals. Each individual biomarker model includes age and gender (except univariate age and gender models) and was compared against a standard model including only age and gender. Regressions were fit using all associated dummy variables for a given biomarker (e.g. 'Mild', 'Moderate', 'Severe') using 'Normal' as the reference. Only complete cases of training data available for that marker were considered, i.e. we did not include data for variables marked 'Test not taken'.

# Analysis Using All Valid Biomarker Data

After individual biomarker evaluation, logistic regression models considering all valid biomarkers (Results Section c) and demographic variables were fit to the data. Their predictions were tested via internal and external validation using cross-validation procedures, additionally we fit models that used all available training data. The models include a standard logistic regression, a logistic regression regularised with LASSO, and two Bayesian models using a flat and a horseshoe prior [22]. LASSO and Bayesian horseshoe prior models (with projective prediction) and regularization constraints that push models to converge on sparse solutions with most coefficients near zero, and lend themselves to variable reduction as discussed in the Reduced Variable Models Section c.

# Analysis Using Reduced Variable Models

While a model using all biomarker data may have strong predictive power, it is clinically desire-able to have a strong prediction with the least amount of biomarkers possible to save on resources devoted to biomarker collection. We used two methodologies to choose reduced variable models to predict COVID-19 severe outcomes, LASSO and Bayesian Projective Prediction.

LASSO is an optimization constraint that shrinks parameters according to their variance, reduces over-fitting, and enables variable selection [18]. The optimal degree of regularisation is determined for each cross-by identifying a tuning parameter  $\lambda$  within a LASSO specific inner loop of each cross-validation step. LASSO has a drawback of having biased coefficient and log-odds estimates, as such after evaluating LASSO models we run a final 'LASSO inspired' standard GLM model.

To evaluate LASSO coefficient estimates, we performed repeated nested cross-validation (5-folds the for the inner LASSO loop; 5-folds for the outer loop, and 20 repeats).

For a particular dataset fit, LASSO optimises for a sparse representation with many coefficients close to zero. Across cross-validated trials these variables will vary. LASSO fits are statistically biased and are better suited as a guide for variable selection in a reduced variable standard GLM. As recommended in Heinze et al [23], we consider the frequency of how

Biomarker	Abbreviation	Place Recorded / Reason	No. of	% of	Reference Range/ Criteria	Clinical Categories	Criteria Description
Blood Clotting Tests		·	Readings	Patients		_	·
Activated partial				ı			Normal: <33; Mild: 33-49.5; Moderate:
thromboplastin time	APTT	Admisson	422	50%	Normal between 21-33 seconds	Normal, Abnormal	49.5-82.5; Severe: >82.5
·					Normal between 9.5-13		·
Prothrombin Time	PT	Admisson	435	52%	seconds	Normal, Abnormal	Abnormal: >=13
Blood Gas Tests							
Carbon Dioxide	CO2	Arterial/ Point of care	154	18%	Normal: 4.6-6.4 seconds	Normal, Abnormal	Abnormal if outside range
Lactate	poctLAC	Arterial/ Point of care	154	18%	0.5-2.2 mmol/L	Normal, Abnormal	Abnormal if <0.5 or >2.2
Oxygen	02	Arterial/ Point of care	154	18%	11.0-14.4 seconds	Normal, Abnormal	Abnormal if <11 or >14.4
Bicarbonate Excess	BE	Arterial or Venous / Point of care	418	50%	22-29	Normal, Abnormal	Abnormal if outside range
pH acid/base scale	рН	Arterial or Venous / Point of care	417	49%	7.35-7.45	Normal, Abnormal	Abnormal if outside these bounds
Coinfection Battery							
Blood Culture	bc_coinfection	Admisson	843	100%	34 bacterial strains tested	Positive, Negative	Postive if one or more postive
Respiratory	resp_coinfection	Admisson	843	100%	34 bacterial strains tested	Positive, Negative	Postive if one or more postive
Urine	urine_coinfection	Admisson	843	100%	34 bacterial strains tested	Positive, Negative	Postive if one or more postive
Viral	viral_coinfection	Admisson	843	100%	10 viral infections tested	Positive, Negative	Postive if one or more postive
Diabetes		1					I
Glucose	Glucose	Point of Care / Record Often Not Digitized	222	26%	Non-fasting: 3.0-7.8 mmol/L	Normal, Abnormal	Abnormal if outside range
Full Blood Count Tests		Orten Not Digitized					
Hemoglobin	НВ	Admisson	772	92%	Male 130-170 g/L, Female 120- 150 g/L	Normal, Mild, Moderate, Severe	Normal: >gender specific criteria; Mild: 100 to gender specific criteria; Moderate: 80-100; Severe: <80
Platelet Count	PLT	Admisson	770	91%	150-450 10^9/L	Normal, Mild, Moderate, Severe	Normal: >150; Mild: 100-150; Moderate: 50-100; Severe: <50
Lymphocytes	Lymphocyte	Admisson	772	92%	1.5-4.5 10^9/L	Normal, Mild, Moderate, Severe	Normal 1.5-4.5; Mild 1-1.5; Moderate 0.5- 1; Severe: <0.5 or >4.5
						Normal, Mild,	Normal 2-7.5; Mild 1-2; Moderate: 0.5-1;
Neutrophils	Neutrophil	Admisson	772	92%	2.0-7.5 10^9/L	Moderate, Severe	Severe: <0.5 or > 7.5
Neutrophil - Lymphocyte			770	020/		Normal, Mild,	Normal: <3; Mild: 3-8; Moderate: 8-18;
Ratio	NLR	Admisson	772	92%	0.78 and 3.53	Moderate, Severe	Severe: >18
White Cell Count	wcc	Admisson	772	92%	4.0-11.0 10^9/L	Normal, Mild,	Normal: 4-11; Mild: 1-4; Moderate: 0.5-1;
White Cell Count	WCC	Aumisson	772	32/0	4.0-11.0 10 <sup>-9</sup> /L	Moderate, Severe	Severe: <0.5 and >11
Urea & Electrolytes Tests							
C-Reactive Protein	CRP	Admisson	759	90%	< 6 mg/L	Normal, Abnormal	Abnormal if greater than criteria
Estimated Glomerular	eGFR	Admisson	707	84%	>90	Normal, Abnormal	Abnormal if greater than criteria
Urea	urea	Admisson	754	89%	2.5-7 10^9/L	Normal, Abnormal	Abnormal if outside these bounds
Investigatory Tests  Brain / B-type natriuretic peptide	BNP	Cardiac Function	47	6%	Men under 70: <100pg/ml, Women under 70: <150 pg/ml, All 70yr and over: <300 pg/ml	Normal, Abnormal	Abnormal if greater than age/gender specific criteria
D-Dimer	DDM		111	13%	Age (Years) D-dimer (ng/ml) <60 <500 61-70 <600 71-80 <700 81-90 <800 >90 <900	Normal, Abnormal	Abnormal if greater than age-specific criteria
Earritin					Male: 33-490, Female(0-44): 15-	Normal, Mild,	Normal: <age appropriate="" criteria;<br="" gender="">Mild: &gt;criteria-735; Moderate: 735-2450;</age>
Ferritin	FER		115	14%	445, Female(45+yrs): 30-470	Moderate, Severe	Severe: >2450
Fibrinogen	FER fib		104	14%	445, Female(45+yrs): 30-470	-	Severe: >2450 Normal: >1.8; Mild: 1-1.8; Severe: <1
		Diabetes				-	
Fibrinogen	fib	Diabetes Investigatory	104	12%	1.8-4.0 g/L	Normal, Mild, Severe.	Normal: >1.8; Mild: 1-1.8; Severe: <1
Fibrinogen Glycated haemoglobin	fib HBA1c		104 17	12%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720;
Fibrinogen Glycated haemoglobin Lactate dehydrogenase	fib HBA1c LDH	Investigatory	104 17 66	12% 2% 8%	1.8-4.0 g/L >=48 mmol/mol	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin	fib HBA1c LDH PCT	Investigatory  ITU / Bacterial Infection	104 17 66 39	12% 2% 8% 5%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild, Moderate, Severe  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440 Abnormal: >=0.2
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides	fib HBA1c LDH PCT trig	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19	12% 2% 8% 5% 2%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440 Abnormal: >=0.2 Abnormal if outside these bounds
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides Troponin-T	fib HBA1c LDH PCT trig	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19	12% 2% 8% 5% 2%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440 Abnormal: >=0.2 Abnormal if outside these bounds
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides Troponin-T Covid-19 Test	fib HBA1c LDH PCT trig trop	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19 177	12% 2% 8% 5% 2% 21%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L Normal: <14ng/L  Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440 Abnormal: >=0.2 Abnormal if outside these bounds Abnormal if greater than criteria
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides Troponin-T Covid-19 Test Covid CT	fib HBA1c LDH PCT trig trop	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19 177	12% 2% 8% 5% 2% 21%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L Normal: <14ng/L  Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1 Abnormal if greater than criteria Normal: <=480; Mild: >480-720; Moderate: >720-1440; Severe: >1440 Abnormal: >=0.2 Abnormal if outside these bounds Abnormal if greater than criteria
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides Troponin-T Covid-19 Test  Covid CT  Other Data Age Gender	fib  HBA1c  LDH  PCT  trig  trop  Covid CT	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19 177	12% 2% 8% 5% 2% 21%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L Normal: <14ng/L  Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal  Normal, Abnormal	Normal: >1.8; Mild: 1-1.8; Severe: <1  Abnormal if greater than criteria  Normal: <=480; Mild: >480-720;  Moderate: >720-1440; Severe: >1440  Abnormal: >=0.2  Abnormal if outside these bounds  Abnormal if greater than criteria  Only positives included in current study
Fibrinogen Glycated haemoglobin Lactate dehydrogenase Procalcitonin Triglycerides Troponin-T Covid-19 Test Covid CT Other Data Age	fib HBA1c LDH PCT trig trop  Covid CT	Investigatory  ITU / Bacterial Infection Investigatory	104 17 66 39 19 177	12% 2% 8% 5% 2% 21%	1.8-4.0 g/L >=48 mmol/mol 240-480 IU/L Normal range: <0.2ng/mL 0.5-1.7 mmol/L Normal: <14ng/L  Threshold unique to type of test. Lab reports categorical 'positive' variable alongside CT	Normal, Mild, Severe.  Normal, Abnormal  Normal, Mild,  Moderate, Severe  Normal, Abnormal  Normal, Abnormal  Positive, Negative  Continuous	Normal: >1.8; Mild: 1-1.8; Severe: <1  Abnormal if greater than criteria  Normal: <=480; Mild: >480-720;  Moderate: >720-1440; Severe: >1440  Abnormal: >=0.2  Abnormal if outside these bounds  Abnormal if greater than criteria  Only positives included in current study

Figure 2: Variables recorded in the LabMarCS dataset, including plain text description, abbreviation, place of record, frequency in the dataset, and criteria used for converting continuous readings into categorical values.

187

188

189

203

207

208

210

211

212

213

214

All rights reserved. No reuse allowed without permission.




Figure 3: Example a single patient's time series laboratory biomarker data. See Figure 2 for biomarker abbreviations. Biomarker results are normalised to span<sup>204</sup> 0 to 1 via offsetting by the absolute value of the minimum value and dividing<sup>205</sup> by the maximum value.




Figure 4: Example distribution of biomarker readings for Neutrophil Training<sup>231</sup> and Validation Data. Vertical lines indicate clinical thresholds for bounds on<sup>232</sup> Normal, Mild, Moderate, and Severe categorization.

often a particular biomarker has a coefficient greater than zero and count across cross-validation trials.

For a 'LASSO inspired' reduced variable standard GLM, it was chosen that if at least one categorical level for a particular biomarker (e.g. 'Severe') met this requirement, all levels for that biomarker were included in the model. This resulted in a final set of variables that could then fit with standard logistic GLM.

The second variable selection method explored was Bayesian projective prediction [19], a technique for constructing an optimal reference model (in our case a Bayesian logistic regression with a horseshoe prior /citecarvalho2009handling over the distribution of coefficient values) that generates a ranking of individual variable informativeness via leave-one-out (LOO) crossvalidation. This ranking of variables can be used to create a projection model where one can arbitrarily remove variables post-hoc. This approach allows one to evaluate the trade-off between AUC performance and the number of variables included in the model and use a reduced model projection at a desired AUC cutoff. Bayesian methods have the benefit of allowing coefficient shrinkage via the horseshoe prior and provide unbiased odds estimates. Further projective prediction allows the flexibility to train one model on all valid available data, perform variable selection, and then use any projected sub-model with reduced variables to predict outcomes for novel data.

#### Results

# Cohort Description

The initial cohort included 1159 patients which was narrowed down to 843 patients who met all inclusion criteria described above, see Figure 1. 57% of patients were hospitalised for COVID-19 and the remainder had nosocomial infection. For our statistical models, the training cohort (n=590) was defined as all adults admitted to hospital and testing positive for SARS-Cov-2 by PCR, or testing positive while already admitted between March and October 2020. For external validation, we held the DGH cohort (n=253) out of training. Figure 5 depicts the distribution of ages and genders in the training and validation data sets. Patients in the training set had a mean age of 70, were 44% female, and 29% had severe outcomes. The validation set had a mean age of 75, were 47% female, and 38% had a severe outcome.

# Prediction Using Individual Variables

Figure 6 shows descriptive statistics on individual biomarker readings and their odds ratio contributions in a 5-fold 20-repeat cross-validated logistic regression including the particular biomarker and age and gender. Figure 7 details performance using the area under the receiver operating characteristic curve (AUC) metric, comparing biomarker models (a particular biomarker plus age and gender) to a model using only age and gender. Due to the categorical representation of the biomarkers, individual levels may be significant while another is not (e.g. 'Severe' is a predictor, but 'Mild' is not). Statistically significant predictors (i.e. odds ratios deviating from one with p-value at

234

235




Figure 5: Distribution of age and gender for hospitalized patients with coronavirus disease 2019 (COVID-19) for (Top) training data (n=590) and (Bottom) hold out validation data (n=253) cohorts.

0.05 or lower) associated with increasing risk of a severe outcome (as shown in Figure 6) include age, and the biomarkers: Activated Partial Thromboplastin Time (Mild), Prothrombin time (Abnormal), blood pH (Abnormal), Haemoglobin (Severe), Platelet count (Moderate), Lymphocytes (Moderate, Severe), Neutrophils (Severe), Neutrophil-Lymphocyte Ratio (Mild, Moderate, Severe), C-Reactive Protein (Abnormal), Urea (Abnormal), and Troponin-T (Abnormal). Nosocomial transmission was included due to the high number of cases in our cohort but was not a significant predictor and excluded from further analyses. Due to small numbers preventing cross validation, Triglycerides, Glycated Haemoglobin, and Procalcitonin (also invalid due to being recorded only in ICU) were excluded from further analysis and require future research.

# Regression Models Using All Valid Biomarker Data

241

242

244

245

248

249

250

251

252

253

255

256

258

259

260

262

263

Each model was evaluated via 5-fold cross-validation with 20 repeats (100 models total). As such, each model is trained with a randomised sample of 80% of the training data set (n=472)0 Internal validation evaluates a model predictions on the 20% 311 (n=118) held out. External validation uses the same model, but 312 is instead tested on the held out validation data set (n=253). 313 Missing data for each biomarker is coded as 'Test Not Taken' 314 and is included as a predictor variable. Figure 8 shows the performance of these models (AUC, Sensitivity, Specificity). For 316 comparison, Figure 9 shows the performance of each model

using all valid training data (n=590) and testing on the same data (internal validation) and testing on the held out external validation data (n=253).

Models trained on the full data have improved AUC scores, but do not provide a direct uncertainty estimate, this could be done via bootstrapping for a single model, but we instead compute inter-quantile ranges across 5-fold 20 repeat cross-validation models. Cross-validation results provide 95% inter-quantile ranges that clearly illustrate that in general, all models perform similarly, with a median AUC in the mid 0.70's in internal validation, and near the high 0.60's in external validation. There is a trend for the models that encourage sparse representations, LASSO and Bayes with horseshoe prior, to have slightly higher AUC's coupled with higher sensitivity and lower specificity. The calibration of the models is reasonably good on the full data, all training data, but has poor calibration on the validation set, see Supplementary Figure S9.

#### Reduced Variable Models

The models detailed above are moderately good predictors of severe COVID-19 outcomes, but for clinicians with limited time and resources, reduced models can balance predictive performance with ease of clinical use by using only the most informative biomarkers. To address this, we use two variable selection approaches, LASSO and projective prediction, that allow the creation of reduced models with fewer biomarkers but similar performance to the larger models.

# LASSO Models

288

After performing 5-fold 20 repeat cross-validation we examined the frequency of how often a particular biomarker has a coefficient greater than zero and count across cross-validation trials. Figure S10 shows the frequency of variables having a coefficient great than zero in the cross-validated LASSO analysis. If we select variables that appear at least 50% of the time, our reduced model would include: Age, CRP (abnormal), FER (mild), FIB (mild), HB (severe), PLT (mild, moderate, severe), Lymphocytes (Severe), Neutrophils (Mild, Severe), NLR (Severe), APTT (mild, moderate), PT (abnormal), blood pH (abnormal), Urea (abnormal), and positive viral and blood culture co-infections.

For a 'LASSO inspired' reduced variable standard GLM, this resulted in a model using the 15 biomarkers above for all categorical levels, and was evaluated via both cross-validation and as fit to all available training data. This model had performance very similar to the models using all valid biomarker data, with a median external validation AUC of 0.68 [0.63, 0.72], see Figures 8 and 9.

Note, 'Test Not Taken' is a significant predictor for LDH and Lactate on over 50% of cross-validation trials. The potential significance of missing data is complex and is addressed in the Discussion Sectionc. Due to this confounding, biomarkers whose top predictive contribution was from 'Test Not Taken' were excluded from both LASSO reduced variable models and projective prediction models described below.

306

					Sta	andard Logistic GLM	Bayesian Logistic (Flat Prior)	Bayesian Logistic (Horse Shoe Prior)
Biomarker	Binary Categorical Variable	% of Patients with Biomarker Recording	# TRUE (% of TRUE Observations with Severe Outcome)	# FALSE (% of FALSE Observations with Severe Outcome)	P Value	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]	Odds Ratio [2.5%, 97.5%]
Demographics / Other								
Age	-	100%	-	-	3.22E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
Gender	Female	100%	257 (26%)	333 (32%)	0.08	0.72 [0.50, 1.03]	0.72 [0.50, 1.03]	0.79 [0.54, 1.06]
Age & Gender	-	100%	-	-	2.83E-05	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]	1.02 [1.01, 1.04]
	Female		257 (26%)	333 (32%)	0.06	0.70 [0.49, 1.02]	0.70 [0.49, 1.00]	0.82 [0.55, 1.07]
Nosocomial Transmission	TRUE	100%	240 (30%)	350 (29%)	0.65	0.92 [0.63, 1.33]	0.92 [0.63, 1.33]	0.98 [0.74, 1.19]
Blood Clotting Tests								
Activated partial	Mild	54%	30 (63%)	291 (320%)	2.44E-03	3.44 [1.57, 7.88]	3.44 [1.55, 7.86]	2.89 [1.12, 6.44]
thromboplastin time	Moderate	54%	4 (100%)	317 (34%)	0.98	9.91E+06 [0.00, NA]	4.4E+104 [5.4E+04, Inf]	7.86 [0.92, 464.23]
Prothrombin Time	Abnormal	56%	45 (58%)	288 (31%)	2.96E-03	2.73 [1.41, 5.36]	2.79 [1.44, 5.37]	2.26 [1.01, 4.63]
Blood Gas Tests		1 20/1	10 (00/1)	200 (02/1)				
Carbon Dioxide	Abnormal	21%	68 (59%)	57 (51%)	0.33	1.44 [0.70, 2.99]	1.46 [0.72, 3.02]	1.08 [0.82, 1.95]
Lactate	Abnormal	21%	13 (54%)	112 (55%)	0.96	1.03 [0.32, 3.44]	1.04 [0.33, 3.40]	1.02 [0.61, 1.80]
Oxygen	Abnormal	21%	105 (55%)	20 (55%)	0.98	1.01 [0.38, 2.66]	1.00 [0.37, 2.68]	0.99 [0.63, 1.53]
Bicarbonate Excess	Abnormal	64%	123 (38%)	252 (31%)	0.26	1.30 [0.82, 2.05]	1.31 [0.84, 2.04]	1.09 [0.87, 1.65]
pH acid/base scale	Abnormal	63%	136 (46%)	238 (26%)	1.05E-04	2.45 [1.56, 3.87]	2.48 [1.58, 3.97]	2.19 [1.34, 3.53]
Coinfection								
Blood Culture	TRUE	100%	5 (0%)	585 (30%)	0.98	3.20E-07 [NA, 2.94E+22]	0 [0, 0]	0.42 [0.02, 1.40]
Respiratory	TRUE	100%	6 (50%)	584 (29%)	0.20	2.95 [0.52, 16.62]	2.96 [0.46, 18.46]	1.23 [0.70, 4.76]
Urine	TRUE	100%	12 (25%)	579 (30%)	0.63	0.72 [0.15, 2.53]	0.63 [0.13, 2.56]	0.94 [0.38, 2.03]
Viral	TRUE	100%	7 (71%)	583 (29%)	0.06	4.95 [1.04, 35.13]	5.93 [1.01, 45.18]	1.82 [0.83, 10.36]
Diabetes	I.i.		40 (450()	105 (000)	1	4 == (0 00 0 54)	4 77 (0 00 0 56)	4 22 [2 22 2 23]
Glucose Full Blood Count Tests	Abnormal	30%	49 (45%)	126 (32%)	0.11	1.77 [0.88, 3.54]	1.77 [0.88, 3.56]	1.28 [0.88, 2.63]
Full Blood Count Tests	In a : Lad	ı	176 (260/)	260 (270/)	I 0.12	1 20 [0 01 2 00]	1 20 [0 01 2 10]	1 12 [0 00 1 72]
Hemoglobin	Mild Moderate	92%	176 (36%) 48 (33%)	368 (27%) 495 (30%)	0.13 0.62	1.38 [0.91, 2.08] 1.19 [0.59, 2.29]	1.38 [0.91, 2.10] 1.18 [0.59, 2.30]	1.13 [0.90, 1.72] 1.02 [0.71, 1.61]
Hemoglobin	Severe	92%	11 (55%)	532 (30%)	0.02	4.08 [1.16, 15.06]	4.26 [1.17, 16.54]	1.57 [0.82, 6.68]
	Mild		67 (39%)	474 (29%)	0.07	1.65 [0.95, 2.83]	1.64 [0.93, 2.79]	1.32 [0.90, 2.30]
Platelet Count	Moderate	92%	17 (65%)	524 (29%)	0.01	4.21 [1.54, 12.65]	4.42 [1.59, 13.10]	2.58 [0.96, 8.72]
	Severe	İ	4 (75%)	537 (30%)	0.12	6.16 [0.76, 126.83]	9.29 [0.82, 245.54]	1.77 [0.65, 14.71]
	Mild		151 (27%)	392 (31%)	0.12	1.69 [0.89, 3.34]	1.70 [0.87, 3.35]	1.10 [0.76, 1.98]
Lymphocytes	Moderate	92%	217 (31%)	326 (30%)	0.03	1.96 [1.07, 3.75]	1.99 [1.08, 3.81]	1.22 [0.88, 2.26]
	Severe		84 (48%)	459 (27%)	4.99E-04	3.48 [1.75, 7.17]	3.53 [1.75, 7.20]	2.08 [1.00, 4.34]
	Mild		23 (13%)	520 (31%)	0.23	0.47 [0.11, 1.43]	0.40 [0.09, 1.35]	0.76 [0.26, 1.32]
Neutrophils	Moderate	92%	3 (33%)	540 (30%)	0.67	1.71 [0.08, 19.15]	1.27 [0.03, 21.43]	1.01 [0.28, 3.66]
	Severe		143 (41%)	400 (26%)	1.88E-03	1.92 [1.27, 2.91]	1.94 [1.28, 2.89]	1.72 [1.08, 2.71]
Neutrophil - Lymphocyte	Mild Moderate	92%	237 (28%)	306 (32%) 406 (27%)	3.69E-03 3.18E-05	2.50 [1.38, 4.79]	2.57 [1.39, 4.98]	1.84 [0.99, 3.50]
Ratio	Severe	92%	137 (39%) 54 (54%)	489 (28%)	2.61E-06	3.97 [2.12, 7.81] 6.38 [2.99, 14.14]	4.13 [2.19, 8.29] 6.69 [3.13, 15.02]	2.92 [1.44, 5.76] 4.52 [1.99, 10.44]
	Mild		57 (23%)	486 (31%)	0.34	0.72 [0.36, 1.38]	0.71 [0.36, 1.37]	0.86 [0.46, 1.23]
White Cell Count	Moderate	92%	2 (50%)	541 (30%)	0.45	3.03 [0.11, 83.24]	3.08 [0.08, 122.91]	1.14 [0.42, 4.94]
	Severe	1	85 (42%)	458 (28%)	0.02	1.84 [1.12, 3.00]	1.84 [1.12, 3.02]	1.50 [0.96, 2.77]
Urea & Electrolytes Tests							•	•
C-Reactive Protein	Abnormal	91%	489 (33%)	47 (4%)	1.49E-03	10.23 [3.08, 63.44]	13.12 [3.39, 87.29]	7.45 [2.52, 33.50]
Estimated Glomerular Filtration Rate	Abnormal	82%	350 (38%)	131 (18%)	0.06	1.76 [0.98, 3.23]	1.80 [0.99, 3.31]	1.38 [0.88, 2.70]
Urea	Abnormal	89%	262 (47%)	264 (15%)	4.23E-11	4.27 [2.79, 6.63]	4.33 [2.82, 6.73]	4.09 [2.67, 6.41]
Investigatory Tests								
Brain / B-type natriuretic	Abnormal	7%	30 (53%)	14 (29%)	0.13	3.91 [0.73, 27.00]	4.65 [0.77, 31.41]	1.53 [0.73, 8.01]
peptide								
D-Dimer	Abnormal	12%	52 (42%)	18 (33%)	0.67	1.29 [0.40, 4.43]	1.32 [0.40, 4.79]	1.08 [0.59, 2.48]
Familia	Mild	14%	11 (64%)	72 (39%)	0.09	3.61 [0.84, 17.70]	4.17 [0.88, 20.84]	1.30 [0.81, 4.78]
Ferritin	Moderate	14%	28 (46%)	55 (40%) 77 (43%)	0.27	1.79 [0.64, 5.15]	1.87 [0.63, 5.55]	1.10 [0.72, 2.38]
	Severe Mild	14% 5%	6 (33%) 4 (75%)	26 (46%)	0.94 0.10	0.93 [0.11, 5.90] 11.27 [0.85, 360.85]	0.85 [0.10, 5.65] 25.22 [1.14, 1.05E+03]	0.94 [0.36, 1.70] 1.44 [0.60, 9.96]
Fibrinogen	Severe	5%	3 (67%)	27 (48%)	0.40	3.41 [0.23, 105.85]	5.42 [0.21, 308.55]	1.11 [0.46, 4.62]
Glycated haemoglobin*	Abnormal	3%	11 (9%)	4 (0%)	1.00	2.98E+08 [0, NA]	2.2E+07 [0.23, 1.3E+39]	1.42 [0.36, 22.68]
la shaha di la la	Mild	6%	12 (67%)	25 (56%)	0.49	2.61 [0.19, 71.00]	3.93 [0.18, 134.47]	1.14 [0.59, 3.50]
Lactate dehydrogenase	Moderate	6%	16 (63%)	21 (57%)	0.78	1.49 [0.10, 40.47]	1.90 [0.08, 64.73]	1.00 [0.41, 2.27]
	Severe	6%	5 (60%)	32 (59%)	0.34	4.63 [0.22, 178.20]	8.20 [0.25, 502.08]	1.08 [0.43, 3.96]
Procalcitonin*	Abnormal	4%	21 (86%)	4 (100%)	1.00	1.15E-07 [NA, 1.6E+184]	3.2E-08 [3.07E-39, 7.82]	0.80 [0.08, 2.84]
Triglycerides*	Abnormal	3%	10 (90%)	5 (100%)	1.00	1.68E-09 [NA, Inf]	2.1E-06 [5.62E-26, 1.46]	0.75 [0.05, 2.88]
Troponin-T	Abnormal	24%	91 (44%)	51 (22%)	0.03	2.96 [1.17, 7.96]	3.09 [1.17, 8.48]	1.75 [0.94, 4.94]

<sup>\*</sup> Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 6: Individual biomarker evaluation including descriptive statistics and logistic regression model outcomes (Standard, Bayesian with flat prior, and Bayes with horseshoe prior), including age and gender (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. normal, mild, moderate, severe) and using only complete cases of training data, i.e. not using a variable for 'Test not taken.' Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.

	Standard Logistic GLM		Bayesian Log	gistic (Flat Prior)	Bayesian Logistic (Horse Shoe Prior)			
		ted 80/20 Split		ted 80/20 Split		Cross-Validated 80/20 Split		
Demographic / Biomarker	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]	Median AUC [2.5%,97.5%]	Median AUC Difference to Age & Gender Standard [2.5%,97.5%]		
Demographics / Other								
Age	0.62 [0.48, 0.71]	0.00, [-0.11, 0.04]	0.62 [0.46, 0.71]	0.00 [-0.10, 0.07]	0.62 [0.45, 0.70]	0.00 [-0.06, 0.09]		
Gender	0.55 [0.45, 0.63]	0.08, [-0.05, 0.17]	0.56 [0.48, 0.64]	0.05 [-0.08, 0.14]	0.55 [0.44, 0.63]	0.07 [-0.14, 0.21]		
Age & Gender	0.61 [0.50, 0.72]	0.00, [0.00, 0.00]	0.61 [0.48, 0.72]	0.00 [-0.02, 0.02]	0.61 [0.45, 0.72]	0.00 [-0.03, 0.02]		
Nosocomial Transmission	0.61 [0.46, 0.73]	0.00, [-0.01, 0.05]	0.61 [0.48, 0.73]	0.00 [-0.02, 0.04]	0.61 [0.46, 0.72]	0.00 [-0.07, 0.02]		
Blood Clotting Tests								
Activated partial								
thromboplastin time	0.66 [0.45, 0.78]	-0.05, [-0.22, 0.04]	0.66 [0.45, 0.78]	-0.04 [-0.23, 0.04]	0.65 [0.45, 0.75]	-0.05 [-0.20, 0.05]		
Prothrombin Time	0.64 [0.50, 0.76]	-0.03 [-0.15, 0.05]	0.64 [0.50, 0.76]	-0.03 [-0.15, 0.05]	0.63 [0.44, 0.76]	-0.03 [-0.13, 0.05]		
Blood Gas Tests	•			•	•			
Carbon Dioxide	0.56 [0.40, 0.76]	0.01 [-0.13, 0.15]	0.55 [0.43, 0.76]	0.02 [-0.18, 0.17]	0.55 [0.44, 0.74]	0.02 [-0.20, 0.18]		
Lactate	0.57 [0.44, 0.79]	0.00 [-0.09, 0.19]	0.58 [0.40, 0.75]	-0.01 [-0.24, 0.17]	0.55 [0.37, 0.81]	0.00 [-0.25, 0.16]		
Oxygen	0.56 [0.44, 0.78]	0.00 [-0.18, 0.11]	0.56 [0.43, 0.77]	0.00 [-0.16, 0.13]	0.58 [0.45, 0.75]	0.00 [-0.21, 0.14]		
Bicarbonate Excess	0.58 [0.43, 0.71]	0.00 [-0.12, 0.14]	0.58 [0.42, 0.71]	0.00 [-0.17, 0.16]	0.60 [0.44, 0.70]	0.00 [-0.07, 0.11]		
pH acid/base scale	0.64 [0.43, 0.75]	-0.05 [-0.22, 0.10]	0.64 [0.45, 0.75]	-0.06 [-0.22, 0.09]	0.64 [0.46, 0.75]	-0.05 [-0.16, 0.08]		
Coinfection					. , ,			
Blood Culture	0.62 [0.46, 0.73]	-0.01 [-0.02, 0.00]	0.62 [0.48, 0.73]	-0.01 [-0.03, 0.01]	0.62 [0.47, 0.72]	0.00 [-0.02, 0.02]		
Respiratory	0.61 [0.49, 0.73]	0.00 [-0.02, 0.02]	0.62 [0.50, 0.74]	0.00 [-0.04, 0.02]	0.62 [0.47, 0.72]	0.00 [-0.02, 0.03]		
Urine	0.61 [0.49, 0.71]	0.00 [-0.01, 0.02]	0.61 [0.47, 0.71]	0.00 [-0.02, 0.03]	0.62 [0.46, 0.72]	0.00 [-0.02, 0.02]		
Viral	0.62 [0.43, 0.71]	0.00 [-0.01, 0.01]	0.62 [0.44, 0.71]	0.00 [-0.03, 0.05]	0.62 [0.46, 0.71]	0.00 [-0.03, 0.02]		
Diabetes	[0, 0]		0.02 (0.0.) 0.02		0.02 (0.00) 0.02	[,]		
Glucose	0.61 [0.45, 0.78]	-0.02 [-0.10, 0.14]	0.61 [0.47, 0.78]	-0.02 [-0.09, 0.09]	0.61 [0.45, 0.78]	-0.01 [-0.21, 0.12]		
Full Blood Count Tests		, , ,	, , , , , ,			, , , ,		
Hemoglobin	0.62 [0.48, 0.71]	-0.01 [-0.05, 0.04]	0.62 [0.49, 0.71]	-0.01 [-0.05, 0.05]	0.62 [0.48, 0.71]	0.00 [-0.04, 0.03]		
Platelet Count	0.64 [0.48, 0.74]	-0.01 [-0.07, 0.06]	0.64 [0.52, 0.74]	-0.02 [-0.06, 0.05]	0.64 [0.46, 0.74]	-0.01 [-0.12, 0.06]		
Lymphocytes	0.65 [0.55, 0.73]	-0.04 [-0.10, 0.04]	0.65 [0.55, 0.73]	-0.04 [-0.10, 0.05]	0.64 [0.52, 0.72]	-0.02 [-0.07, 0.02]		
Neutrophils	0.63 [0.55, 0.72]	-0.02 [-0.12, 0.06]	0.63 [0.53, 0.72]	-0.02 [-0.08, 0.07]	0.63 [0.54, 0.72]	-0.03 [-0.19, 0.05]		
Neutrophil - Lymphocyte	0.03 [0.33, 0.72]	0.02 [ 0.12, 0.00]	0.03 [0.33, 0.72]	0.02 [ 0.00, 0.07]	0.03 [0.3 1, 0.72]	0.03 [ 0.13, 0.03]		
Ratio	0.67 [0.57, 0.76]	-0.06 [-0.16, 0.06]	0.67 [0.57, 0.77]	-0.06 [-0.15, 0.06]	0.67 [0.56, 0.76]	-0.06 [-0.11, 0.04]		
White Cell Count	0.62 [0.48, 0.72]	0.00 [-0.09, 0.08]	0.62 [0.48, 0.72]	0.00 [-0.08, 0.08]	0.62 [0.46, 0.74]	-0.01 [-0.05, 0.08]		
Urea & Electrolytes Tests								
C-Reactive Protein	0.65 [0.45, 0.74]	-0.03 [-0.08, 0.03]	0.65 [0.44, 0.74]	-0.03 [-0.09, 0.04]	0.65 [0.44, 0.74]	-0.04 [-0.15, 0.05]		
Estimated Glomerular Filtration Rate	0.62 [0.53, 0.71]	-0.01 [-0.03, 0.04]	0.62 [0.52, 0.71]	-0.01 [-0.04, 0.04]	0.62 [0.51, 0.71]	0.00 [-0.04, 0.05]		
Urea	0.71 [0.59, 0.80]	-0.09 [-0.18, -0.02]	0.71 [0.59, 0.80]	-0.09 [-0.19, -0.01]	0.71 [0.59, 0.81]	-0.09 [-0.20, -0.01]		
Investigatory Tests								
Brain / B-type natriuretic peptide	0.67 [0.44, 0.94]	-0.05 [-0.33, 0.25]	0.67 [0.45, 0.94]	0.00 [-0.33, 0.22]	0.65 [0.40, 0.94]	0.00 [-0.33, 0.25]		
D-Dimer	0.62 [0.44, 0.85]	0.01 [-0.15, 0.24]	0.63 [0.43, 0.83]	0.00 [-0.21, 0.22]	0.65 [0.42, 0.89]	0.00 [-0.10, 0.17]		
Ferritin	0.61 [0.44, 0.83]	-0.01 [-0.26, 0.21]	0.61 [0.45, 0.83]	0.00 [-0.29, 0.20]	0.58 [0.43, 0.80]	-0.01 [-0.31, 0.20]		
Fibrinogen	0.67 [0.38, 1.00]	0.00 [-0.44, 0.50]	0.75 [0.38, 1.00]	0.00 [-0.40, 0.44]	0.75 [0.38, 1.00]	0.00 [-0.44, 0.33]		
Glycated haemoglobin*	NA	NA	NA	NA	NA	NA		
Lactate dehydrogenase	0.67 [0.40, 1.00]	0.00 [-0.42, 0.33]	0.67 [0.40, 1.00]	0.00 [-0.42, 0.40]	0.67 [0.30, 1.00]	0.00 [-0.25, 0.25]		
Procalcitonin*	NA	NA	NA	NA	NA	NA		
Triglycerides*	NA	NA	NA	NA	NA	NA		
Troponin-T	0.57 [0.40, 0.77]	-0.01 [-0.22, 0.20]	0.57 [0.40, 0.76]	-0.01 [-0.25, 0.18]	0.59 [0.43, 0.78]	-0.01 [-0.25, 0.13]		

<sup>\*</sup> Biomarkers not included in subsequent models due to small sample size, and recorded only in ICU (PCT)

Figure 7: Predictive performance of the individual biomarker models in Figure 6 as described by the median area under the curve (AUC) in receiver operating curve (ROC) analysis and median difference between an Age and Gender reference model and the same model with the particular biomarker included (except univariate age and gender models). Regressions were fit using all associated dummy variables for a given biomarker (e.g. mild, moderate, severe) and using only complete cases of training data (n=590), i.e. not using a variable for 'Test not taken.' 95% inter-quantile ranges calculated via 5-fold cross-validation with 20 repeats (100 models total). Categorical variables use a reading of 'Normal' as a reference in the fitted model, except 'Male' used as the reference category for gender.

		Internal Validation	External Validation			
Model	AUC [2.5%, 97.5%]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]	AUC [2.5, 97.5]	Specificity at 90% Sensitivity [2.5%, 97.5%]	Specificity at 95% Sensitivity [2.5%, 97.5%]
Standard Logistic GLM	0.70 [0.64, 0.81]	0.39 [0.04, 0.57]	0.20 [0.00, 0.50]	0.67 [0.61, 0.71]	0.28 [0.16, 0.39]	0.13 [0.01, 0.24]
Standard GLM with LASSO regularisation	0.77 [0.71, 0.86]	0.46 [0.26, 0.60]	0.35 [0.11, 0.52]	0.69 [0.67, 0.71]	0.32 [0.25, 0.40]	0.19 [0.14, 0.27]
Bayesian GLM (Flat Prior)	0.75 [0.67, 0.82]	0.41 [0.02, 0.60]	0.22 [0.00, 0.49]	0.67 [0.63, 0.71]	0.27 [0.18, 0.38]	0.13 [0.01, 0.24]
Bayesian GLM (Horse Shoe Prior)	0.78 [0.71, 0.85]	0.49 [0.32, 0.67]	0.38 [0.16, 0.59]	0.70 [0.68, 0.71]	0.33 [0.29, 0.39]	0.23 [0.18, 0.26]
LASSO inspired GLM (15 biomarkers)	0.76 [0.35, 0.76]	0.43 [0.08, 0.64]	0.25 [0.01, 0.57]	0.68 [0.63, 0.72]	0.28 [0.20, 0.38]	0.13 [0.03, 0.25]
Projective Prediction (28 Biomarkers)	0.78 [0.70, 0.85]	0.50 [0.29, 0.67]	0.37 [0.14, 0.59]	0.70 [0.68, 0.71]	0.34 [0.30, 0.39]	0.24 [0.18, 0.25]
Projective Prediction (3 Biomarkers)	0.74 [0.67, 0.82]	0.38 [0.18, 0.58]	0.24 [0.08, 0.50]	0.70 [0.69, 0.71]	0.38 [0.18, 0.58]	0.24 [0.08,0.50]

Figure 8: Cross-validated performance of models trained using valid biomarker data. 95% inter-quantile ranges are presented for each estimate. Specificity is obtained by evaluating at a set sensitivity of either 90% or 95%. All reduced variable models include age, and a stated number of biomarkers. The reduced variable LASSO inspired standard GLM uses 15 biomarkers that had non-zero coefficients on >=50% LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses all categorical levels for Urea, PT, and NLR.

	Internal Validation					External Validation				
Model	Accuracy	AUC	Brier	Sensitivity	Specificity	Accuracy	AUC	Brier	Sensitivity	Specificity
Standard Logistic GLM	0.82	0.87	0.13	0.93	0.56	0.66	0.69	0.13	0.82	0.40
Standard GLM with LASSO regularisation	0.77	0.83	0.23	0.94	0.39	0.62	0.69	0.38	0.93	0.13
LASSO inspired GLM (15 biomarkers)	0.79	0.84	0.14	0.91	0.50	0.67	0.69	0.14	0.88	0.34
Bayesian GLM (Flat Prior)	0.82	0.86	0.18	0.92	0.58	0.64	0.68	0.36	0.79	0.40
Bayesian GLM (Horse Shoe Prior)	0.79	0.84	0.21	0.94	0.45	0.63	0.71	0.37	0.89	0.22
Projective Prediction (28 Biomarkers)	0.79	0.83	0.21	0.94	0.44	0.64	0.71	0.36	0.90	0.24
Projective Prediction (3 Biomarkers)	0.73	0.75	0.27	0.91	0.30	0.67	0.70	0.33	0.94	0.24

Figure 9: Performance of models using all valid biomarker data training data available (n=590). Internal validation is trained on all of the training data and tested on the same. External validation uses the same model and is tested on held out validation data set (n=253). Missing data for each biomarker is coded as 'Test Not Taken'. Specificity and sensitivity evaluated using a probability threshold of 0.5 (i.e. assumes a well-calibrated model). All reduced variable models include age, and a stated number of biomarkers. The reduced variable LASSO inspired standard GLM uses 15 biomarkers that had non-zero coefficients on >=50% LASSO Cross-validation trials. If at least one categorical level for a particular biomarker (e.g. severe) met this requirement, all levels for that biomarker were included in the model. The 3 biomarker projective prediction model uses uses all categorical levels for Urea, PT, and NLR.

### Projective Prediction Models

318

319

320

322

323

324

326

327

328

330

331

332

333

334

335

338

339

341

342

343

346

347

349

350

354

355

358

359

360

362

363

368

When all biomarkers were considered, projective prediction<sup>371</sup> identifies the following predictors in the top 20, in order of con-372 tribution to AUC: Urea (abnormal), Age, PT (abnormal), NLR373 (Severe), pH (abnormal), Lymphocytes (severe), APPT(mild), 374 eGFR (abnormal), Neutrophils (Severe), APPT (moderate), CRP<sup>875</sup> (abnormal), DDM (abnormal), Hemoglobin (severe). Thus age<sup>376</sup> and 12 biomarkers are candidates for a reduced model. Note, several predictors of 'Test Not Taken' were also selected in-377 cluding Lactate, O2, CO2, LDH, Ferritin and Fibrinogen. As<sub>378</sub> mentioned above, these biomarkers are set aside due to this379 confounding. Supplementary Figures S11 and S12 display<sub>380</sub> the output from projective prediction ranking the contribution381 of each variable to the model. A model using a projection in-382 corporating all biomarker and demographic data is equivalent to383 the standard Bayesian GLM we evaluated in the prior section,384 see Figures 8 and 9.

Reduced variable projections were evaluated by manual in-386 spection of AUC performance among groups of models using387 the top biomarkers. Guided by the projective prediction rank-388 ing, we ran a model using only the top biomarker, using only<sup>389</sup> the top two, the top three, and so on. As described above we390 omit biomarkers with significant contributions from 'Test Not391 Taken' and include all categorical levels for a given biomarker392 as long as one level is highly ranked. Ultimately, we found a 3393 biomarker projective prediction model using age and including 394 urea, prothrombin time, neutrophil-lymphocyte ratios had sim-395 ilar performance to larger models with a median internal vali-396 dation AUC of 0.74 [0.67, 0.82], and external validation AUC<sub>397</sub> of 0.70 [0.69, 0.71], as shown in Figures 8 and 9. Odds ra-398 tios for the full Bayesian model and the reduced 3-biomarker399 model can be found in Supplementary Table S13. The calibra-400 tion of the model is reasonably good on the training data but401 has poor calibration on the validation set, see Supplementary<sub>402</sub> Figure S14.

# Discussion

# Challenges of Complex Medical Data

Curating the LabMarCS data is challenging as the data are heterogeneous in multiple ways. Biomarkers are recorded for different reasons, e.g. routine upon admission, investigatory tests, or tests primarily or exclusively taken in ICU. Further some biomarkers are typically recorded together (but not always) as part of a test suite, including: Urea and electrolytes, full blood count, COVID-19 and co-infection swab test, blood clotting, and blood gas tests (arterial or venous). The schedule when some these markers are recorded vary by patient and clin-415 ical decision, leading to records being present in highly varying amounts, e.g. only 3% up to 100% of patients depending on the departicular biomarker, see Supplementary Figure S1.

# Modelling Choices

When constructing and evaluating models, there are many choice points that should be explicitly highlighted with justification, be it based on convenience, computational complexity, 42

clinical advice, or a heuristic. The space of potential models is vast and most studies will constrain the model search space, delineating why these choices are made will facilitate understanding and reproduction by other researchers. These include key choices relating to: patient inclusion/exclusion criteria, data missingness protocols, data transformations, training and validation data selection, and performance evaluation.

#### Missing Data

Missingness, in the context of this study and in healthcare data more generally, can sometimes be informative and missing not at random (MNAR), with the presence or absence of a test correlated with the measurement of said test. Imputation of missing data relies on key statistical assumptions that imputed variables are missing at random (MAR) or missing completely at random (MCAR), else the imputation will be faulty and models may be fit to non-representative data. Conversations with our clinical colleagues established some routinely collected biomarkers might be inferred to be MAR. However, the routines identified were specific to a small a subset of our cohort and not likely to extrapolate. We ultimately erred to be conservative and avoid all imputation, and instead include missing values as a data point [24, 25]. As such, in the current study we chose to use placeholders for 'Test not taken' if there was no recorded value for a particular biomarker within the evaluated 3-day window.

This approach however, allows the possibility that a 'Test Not Taken' may be a significant predictor. This has many potential meanings, as it may convey that when a patient is doing well and unlikely to experience a severe outcome, clinicians are unlikely to request some biomarker tests. Alternatively, if a patient is in palliative care and has a poor prognosis, a clinician may consider further testing unnecessary. As such, the likelihood of a test being administered may follow an inverted-U function as patients to healthy or too ill may not have tests administer. Furthermore, as our data was collected early in the pandemic, there may be other underlying clinical decisions or resource limitations that drove why some tests were taken but not others. Lastly, because we only consider results from the first 3 days from a patients critical date, it may be that some tests are simply taken later in a patient's stay, and hence may be more predictive as they were taken closer to the outcome. Hence, when these instances occurred, we were conservative and excluded biomarkers with 'Test Not Taken' as the most informative category from our reduced variable models.

# Data Transforms - Time Windows

Ideally clinicians can make a decision based on readings the day of admission. However, not all tests are administered on admission. To balance inclusion of test data not available on the day of admission and the need for clinical decisions to be guided soon after admission, we chose to consider the first value recorded for each biomarkers within three days of their 'critical date', i.e. date of admission if already COVID-19 positive, or if already in hospital, the date of testing COVID-19 positive. However, given the richness of the time series data collected,

420

405

406

further research into models that leverage this extra information<sub>477</sub> is needed.

Focusing on early detection reflects the intent for the model<sub>479</sub> to improve early stage clinical decision making when potential<sub>480</sub> treatments or changes in care may be introduced. This focus<sub>481</sub> on the first reading in a 3-day interval loses information, but<sub>482</sub> greatly simplifies the modelling approach. Note, this choice is<sub>483</sub> not without risk of reducing statistical power, increasing the risk<sub>484</sub> of false positives, and underestimation of the extent of variation<sub>485</sub> in biomarker readings and outcomes between groups [26]. It is<sub>486</sub> likely that representing biomarker data as time series (assuming<sub>487</sub> regular measures across patients) instead of single points would<sub>488</sub> add considerable information.

#### Data Transforms - Continuous vs. Categorical

425

426

427

428

429

430

431

433

434

435

437

438

439

440

441

443

444

445

446

447

448

449

451

452

453

455

456

457

459

460

461

463

464

465

466

467

470

471

473

474

475

A key modelling decision must be made on whether to use<sub>491</sub> continuous data or transformed categorical data. Clinicians of-499 ten use biomarker thresholds to provide semantic categories 493 (e.g. normal, mild, moderate, severe) which sometimes use<sub>494</sub> non-linear or discontinuous mappings that require special care if using continuous data. While clinical thresholds are likely 496 established with evidence, it may be the case that thresholds<sub>497</sub> for one use may not apply to a novel one. This led [27, 28]  $to_{498}$ use machine learning approaches to build categorisation models 499 on continuous biomarker data dependent on the training data at hand. However, using machine learning to establish categorisa-500 tion thresholds on our biomarker data is difficult with a small training data set and the heterogeneity of biomarker recordings. If missing data imputation is done, it raises another decision point on whether to impute the continuous or the transformed 503 categorical data.

Another important factor to recognise is that some biomarkers lack a linear relationship between a reading and a semantic category. Biomarkers can have a lower and upper bound
for what is considered normal, and both below and above this
range reflects clinically meaningful yet sometimes separate abnormalities. This means modelling needs to factor in non-linear
curves if persevering continuous data or trying to map to a categorical space. In our position, categorical transforms had the
advantage as we were able to collaborate with ICU consultants
in conjunction with using pre-established clinically acceptable
ranges defined our categorisation, see Figure 2.

#### Training and Validation Data Selection

There are multiple ways that our data set could be split be-517 tween training and validation sets, e.g. randomly sampling 1/3 of the data to hold out as a validation set. Given our rather small sample, random selection of training data should in principle generate data more representative of the validation set left out. However, realistically hospitals may have differing practices and randomization of may inflate performance at the cost of real world validity. We chose to separate our training and validation datasets by hospital to provide a stronger test of generalisation that should mimic generalisation to novel hospitals completely outside the original training data.

### Model Performance Evaluation and Dissemination

There are a variety of ways statistical model performance can be evaluated. Here we have chose here to emphasize cross-validated estimates of AUC, sensitivity, and specificity. Interquartile intervals over these measures reveal that the variety of models perform in similar ways. While the full models have higher median performance, the reduced models are within the 95% bounds of the other models. With a larger data set trade-offs may become more apparent. Model calibration on the validation set is a clear weak point. While the models have decent calibration for training data, generalisation performance is weak and suggestive of the lack of sufficient data.

## Comparison to Contemporary Models

Despite our dataset being relatively small, we found several biomarkers previously highlighted by other groups to have significant predictive power, including: Urea, Neutrophil-Lymphocyte Ratio, Lymphoctyes, APTT, eGFR, and CRP. Our highly reduced 3-biomarker model (plus age) uses Urea (highlighted by all prior models), Neutrophil-Lymphocyte ratio (highlighted by [29, 11, 28]), and APPT (highlighted by [28]). With a larger dataset, further vetting of these and other biomarkers would be possible, but it gives reassurance that despite our data and model limitations, we find similar predictive biomarkers.

# Advantages of Bayesian Modelling

While the predictive performance across models presented here is generally quite similar, there are several reasons for researchers to favor Bayesian approaches. The coefficients estimated via Bayes should on average deliver slightly better predictive performance. Additionally, if a sparse model is needed, a horseshoe prior can provide advantages similar to LASSO without biased coefficient estimates. Computationally, Bayesian techniques can be slow due Markov Chain Monte Carlo used to sample the coefficient space. If one is interested in variable selection, projective prediction offers the ability to take a single Bayesian model fit, run a variable selection algorithm to rank variable contributions, and then arbitrarily create submodel projections with any number of original variables. While the initial model fit and variable selection are computationally intensive, sub-model projections are fast to create and performance test.

# **Summary & Conclusions**

Limitations: This is a retrospective cohort study involving a relatively small cohort in Southwest England where case numbers have varied widely, and were well below national figures during the first wave. This results in less precise parameter estimates for prediction models (less power/smaller sample size) and likely reduced generalizability of the model to other settings. The timing of biomarker collection was highly varied both within and between patients, with many types of readings missing. While we replicated prior findings on several biomarkers, gender was not significant, suggesting our sample may not be representative.

598

599

608

609

610

620

621

622

623

624

626

636

637

Strengths: The primary strength of our study is the granu-576 larity of serial laboratory data available linked to clinical out-577 comes. This study was performed during the first wave where 578 there was the original Wuhan strain circulating amongst the un-580 vaccinated naïve population without any specific immunomod-581 ulating therapies such as steroids or antiviral agents, reflecting 582 the "true" homeostasis derangements at a population level.

This study highlights a variety of challenges present in com-585 plex medical data sets while maintaining best statistical prac-586 tices with an emphasis on recent Bayesian methodology. Our 587 study reiterates the predictive value of previously identified biom 588 cers for COVID-19 severity assessment (e.g. age, urea, pro-590 thrombin time, and neutrophil-lymphocyte ratio). Both the full 591 and reduced variable models have moderately good training 592 performance, but improved external validation is needed for 594 all models to be clinically viable. The methods presented here 596 should generalise well to a larger dataset.

#### Ethics approval

530

531

532

534

535

539

540

542

543

548

549

551

552

553

554

557

558

560

562

563

564

565

567

569

570

571

572

573

574

The study [IRAS project ID: 283439] underwent a rigorous 602 ethical and regulatory approval process, and a favourable opin-603 ion was gained from Research Ethics Service, Wales REC 7,604 c/o Public Health Wales, Building 1, Jobswell Road, St David's 606 Park, SA31 3HB on 11/09/2020.

#### Funding

This work is funded by Health Data Research UK via the<sub>612</sub> Better Care Partnership Southwest (HDR CF0129), Medical<sup>613</sup> Research Council Research Grant MR/T005408/1, and the Eliz-<sup>614</sup> abeth Blackwell Institute for Health Research, University of <sub>616</sub> Bristol and the Wellcome Trust Institutional Strategic Support<sup>617</sup> Fund.

# **Declaration of competing interest**

The authors have no competing interests.

#### Acknowledgements

This research was supported by the National Institute forese Health and Care Research (NIHR) Applied Research Collab-630 oration West (NIHR ARC West). The views expressed in this 632 article are those of the author(s) and not necessarily those of the 633 NIHR or the Department of Health and Social Care.

#### References

A. B. Docherty, E. M. Harrison, C. A. Green, H. Hardwick, R. Pius,<sup>639</sup>
 L. Norman, K. A. Holden, J. M. Read, F. Dondelinger, G. Carson, L. Mer-<sup>640</sup>
 son, J. Lee, D. Plotkin, L. Sigfrid, S. Halpin, C. Jackson, C. Gam-<sup>641</sup>
 ble, P. W. Horby, J. S. Nguyen-Van-Tam, I. Investigators, J. Dunning,<sup>642</sup>
 P. J. M. Openshaw, J. K. Baillie, M. G. Semple, Features of 16,749 hos-<sup>643</sup>
 pitalised UK patients with COVID-19 using the ISARIC WHO Clinical<sup>644</sup>
 Characterisation Protocol, medRxiv (2020) 2020.04.23.20076042doi: <sup>645</sup>
 10.1101/2020.04.23.20076042.

- [2] C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, Y. Song, Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China, JAMA internal medicine 180 (7) (2020) 934–943. doi:10.1001/jamainternmed.2020.0994.
- [3] L. Bowles, S. Platton, N. Yartey, M. Dave, K. Lee, D. P. Hart, V. Mac-Donald, L. Green, S. Sivapalaratnam, K. J. Pasi, P. MacCallum, Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19, New England Journal of Medicine 383 (3) (2020) 288–290. doi: 10.1056/NEJMc2013656.
- [4] N. Tang, D. Li, X. Wang, Z. Sun, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, Journal of thrombosis and haemostasis: JTH 18 (4) (2020) 844– 847. doi:10.1111/jth.14768.
- [5] H. Han, L. Yang, R. Liu, F. Liu, K.-L. Wu, J. Li, X.-H. Liu, C.-L. Zhu, Prominent changes in blood coagulation of patients with SARS-CoV-2 infection, Clinical Chemistry and Laboratory Medicine 58 (7) (2020) 1116–1120. doi:10.1515/cclm-2020-0188.
- [6] X. Bi, Z. Su, H. Yan, J. Du, J. Wang, L. Chen, M. Peng, S. Chen, B. Shen, J. Li, Prediction of severe illness due to COVID-19 based on an analysis of initial Fibrinogen to Albumin Ratio and Platelet count, Platelets 31 (5) (2020) 674–679. doi:10.1080/09537104.2020.1760230.
- [7] F. Liu, L. Li, M. Xu, J. Wu, D. Luo, Y. Zhu, B. Li, X. Song, X. Zhou, Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19, Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 127 (2020) 104370. doi:10.1016/j.jcv.2020.104370.
- [8] G. Vaseghi, M. Mansourian, R. Karimi, K. Heshmat-Ghahdarijani, P. Rouhi, M. Shariati, S. H. Javanmard, Inflammatory markers in Covid-19 Patients: A systematic review and meta-analysis, medRxiv (2020) 2020.04.29.20084863doi:10.1101/2020.04.29.20084863.
- [9] Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China, Intensive Care Medicine 46 (5) (2020) 846–848. doi:10.1007/s00134-020-05991-x.
- [10] B. E. Young, S. W. X. Ong, S. Kalimuddin, J. G. Low, S. Y. Tan, J. Loh, O.-T. Ng, K. Marimuthu, L. W. Ang, T. M. Mak, S. K. Lau, D. E. Anderson, K. S. Chan, T. Y. Tan, T. Y. Ng, L. Cui, Z. Said, L. Kurupatham, M. I.-C. Chen, M. Chan, S. Vasoo, L.-F. Wang, B. H. Tan, R. T. P. Lin, V. J. M. Lee, Y.-S. Leo, D. C. Lye, Singapore 2019 Novel Coronavirus Outbreak Research Team, Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore, JAMA 323 (15) (2020) 1488–1494. doi:10.1001/jama.2020.3204.
- [11] J. Liu, Y. Liu, P. Xiang, L. Pu, H. Xiong, C. Li, M. Zhang, J. Tan, Y. Xu, R. Song, M. Song, L. Wang, W. Zhang, B. Han, L. Yang, X. Wang, G. Zhou, T. Zhang, B. Li, Y. Wang, Z. Chen, X. Wang, Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage, medRxiv (2020) 2020.02.10.20021584doi: 10.1101/2020.02.10.20021584.
- [12] L. E. Gralinski, A. Bankhead, S. Jeng, V. D. Menachery, S. Proll, S. E. Belisle, M. Matzke, B.-J. M. Webb-Robertson, M. L. Luna, A. K. Shukla, M. T. Ferris, M. Bolles, J. Chang, L. Aicher, K. M. Waters, R. D. Smith, T. O. Metz, G. L. Law, M. G. Katze, S. McWeeney, R. S. Baric, Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury, mBio 4 (4) (Aug. 2013). doi:10.1128/mBio.00271-13.
- [13] Z. Xu, L. Shi, Y. Wang, J. Zhang, L. Huang, C. Zhang, S. Liu, P. Zhao, H. Liu, L. Zhu, Y. Tai, C. Bai, T. Gao, J. Song, P. Xia, J. Dong, J. Zhao, F.-S. Wang, Pathological findings of COVID-19 associated with acute respiratory distress syndrome, The Lancet Respiratory Medicine 8 (4) (2020) 420–422. doi:10.1016/S2213-2600(20)30076-X.
- [14] M. Arentz, E. Yim, L. Klaff, S. Lokhandwala, F. X. Riedo, M. Chong, M. Lee, Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State, JAMA 323 (16) (2020) 1612–1614. doi:10.1001/jama.2020.4326.
- [15] N. Wilson, A. Kvalsvig, L. T. Barnard, M. G. Baker, Case-Fatality Risk Estimates for COVID-19 Calculated by Using a Lag Time for Fatality - Volume 26, Number 6—June 2020 - Emerging Infectious Diseases journal - CDC, Emerging Infectious Diseases (2020). doi:10.3201/ eid2606.200320.

[16] H. Barrasa, J. Rello, S. Tejada, A. Martín, G. Balziskueta, C. Vinuesa, B. Fernández-Miret, A. Villagra, A. Vallejo, A. San Sebastián, S. Cabañes, S. Iribarren, F. Fonseca, J. Maynar, Alava COVID-19 Study Investigators, SARS-CoV-2 in Spanish Intensive Care Units: Early experience with 15-day survival in Vitoria, Anaesthesia, Critical Care & Pain Medicine 39 (5) (2020) 553–561. doi:10.1016/j.accpm.2020.04.001.

- [17] L. Wynants, B. V. Calster, G. S. Collins, R. D. Riley, G. Heinze, E. Schuit, M. M. J. Bonten, D. L. Dahly, J. A. Damen, T. P. A. Debray, V. M. T. de Jong, M. D. Vos, P. Dhiman, M. C. Haller, M. O. Harhay, L. Henckaerts, P. Heus, M. Kammer, N. Kreuzberger, A. Lohmann, K. Luijken, J. Ma, G. P. Martin, D. J. McLernon, C. L. A. Navarro, J. B. Reitsma, J. C. Sergeant, C. Shi, N. Skoetz, L. J. M. Smits, K. I. E. Snell, M. Sperrin, R. Spijker, E. W. Steyerberg, T. Takada, I. Tzoulaki, S. M. J. van Kuijk, B. C. T. van Bussel, I. C. C. van der Horst, F. S. van Royen, J. Y. Verbakel, C. Wallisch, J. Wilkinson, R. Wolff, L. Hooft, K. G. M. Moons, M. van Smeden, Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal, BMJ 369 (2020) m1328. doi:10.1136/bmj.m1328.
- [18] R. Tibshirani, Regression Shrinkage and Selection Via the Lasso, Journal of the Royal Statistical Society: Series B (Methodological) 58 (1) (1996) 267–288. doi:10.1111/j.2517-6161.1996.tb02080.x.
- [19] J. Piironen, M. Paasiniemi, A. Vehtari, Projective inference in high-dimensional problems: Prediction and feature selection, Electronic Journal of Statistics 14 (1) (2020) 2155–2197. doi:10.1214/20-EJS1711.
- [20] J. C. Marshall, S. Murthy, J. Diaz, N. Adhikari, D. C. Angus, Y. M. Arabi, K. Baillie, M. Bauer, S. Berry, B. Blackwood, et al., A minimal common outcome measure set for covid-19 clinical research, The Lancet Infectious Diseases 20 (8) (2020) e192–e197.
- [21] M. van der Schaar Lab, Time series in healthcare: challenges and
   solutions, https://www.vanderschaar-lab.com/time-series-in-healthcare/
   (2022).
  - [22] C. M. Carvalho, N. G. Polson, J. G. Scott, Handling sparsity via the horseshoe, in: Artificial Intelligence and Statistics, PMLR, 2009, pp. 73–80.
  - [23] Variable selection A review and recommendations for the practicing statistician - Heinze - 2018 - Biometrical Journal - Wiley Online Library, https://onlinelibrary.wiley.com/doi/full/10.1002/bimj.201700067 (2018).
- [24] R. H. Groenwold, Informative missingness in electronic health record systems: the curse of knowing, Diagnostic and prognostic research 4 (1) (2020) 1–6.
  - [25] S. Van Buuren, Flexible imputation of missing data, CRC press, 2018.
  - [26] D. G. Altman, P. Royston, The cost of dichotomising continuous variables, BMJ: British Medical Journal 332 (7549) (2006) 1080.
  - [27] S. R. Knight, A. Ho, R. Pius, I. Buchan, G. Carson, T. M. Drake, J. Dunning, C. J. Fairfield, C. Gamble, C. A. Green, et al., Risk stratification of patients admitted to hospital with covid-19 using the isaric who clinical characterisation protocol: development and validation of the 4c mortality score, bmj 370 (2020).
  - [28] J. Zhou, S. Lee, X. Wang, Y. Li, W. K. K. Wu, T. Liu, Z. Cao, D. D. Zeng, K. S. K. Leung, A. K. C. Wai, et al., Development of a multivariable prediction model for severe covid-19 disease: a population-based study from hong kong, NPJ digital medicine 4 (1) (2021) 1–9.
  - [29] E. Carr, R. Bendayan, D. Bean, M. Stammers, W. Wang, H. Zhang, T. Searle, Z. Kraljevic, A. Shek, H. T. T. Phan, W. Muruet, R. K. Gupta, A. J. Shinton, M. Wyatt, T. Shi, X. Zhang, A. Pickles, D. Stahl, R. Zakeri, M. Noursadeghi, K. O'Gallagher, M. Rogers, A. Folarin, A. Karwath, K. E. Wickstrøm, A. Köhn-Luque, L. Slater, V. R. Cardoso, C. Bourdeaux, A. R. Holten, S. Ball, C. McWilliams, L. Roguski, F. Borca, J. Batchelor, E. K. Amundsen, X. Wu, G. V. Gkoutos, J. Sun, A. Pinto, B. Guthrie, C. Breen, A. Douiri, H. Wu, V. Curcin, J. T. Teo, A. M. Shah, R. J. B. Dobson, Evaluation and improvement of the National Early Warning Score (NEWS2) for COVID-19: A multi-hospital study, BMC Medicine 19 (1) (2021) 23. doi:10.1186/s12916-020-01893-3.

# Supplementary materials




Figure S1: Heat map displaying missing values across recorded biomarkers. Light blue indicates a value is missing and dark blue indicate it is present




Figure S2: Example biomarker time series for a patient admitted to hospital COVID-19 positive and who subsequently died almost two weeks later.




Figure S3: Example biomarker time series for a patient admitted to hospital with subsequent nosocomial transmission and discharge a week later.




Figure S4: Example biomarker time series for a patient admitted to hospital COVID-19 positive, with subsequent entrance to ICU and death over one month later.




Figure S5: Example biomarker time series for a patient admitted to hospital and ICU, with subsequent nosocomial transmission and discharge about one week later.




Figure S7: Distribution of D-Dimer readings with clinical classification requiring age and gender bands




Figure S6: Example biomarker time series for a patient with two hospital admissions and testing COVID-19 positive on the first, with discharge almost two weeks after second admission.

Biomarker	Binary Categorical Variable	P-Value	Odds Ratio CI [2.5%, 97.5%]
Demographics / Other			
Age	-	6.30E-05	1.04 [1.02, 1.06]
Gender	Female	0.43	1.21 [0.75, 1.97]
Blood Clotting Tests			
Activated partial	Mild	0.07	2.79 [0.93, 8.35]
thromboplastin time	Moderate Not Taken	0.50	3.23E+07 [0, Inf] 0.45 [0.05, 4.51]
	Abnormal	0.16	2.02 [0.75, 5.44]
Prothrombin Time	Not Taken	0.46	2.38 [0.24, 23.86]
Blood Gas Tests			
	Abnormal	0.80	1.13 [0.44, 2.95]
Carbon Dioxide	Not Taken	NA	NA
Lactate	Abnormal	0.63	0.67 [0.13, 3.34]
Lactate	Not Taken	0.02	0.16 [0.04, 0.72]
Oxygen	Abnormal	0.95	1.05 [0.26, 4.15]
- 70-	Not Taken	NA	NA
Bicarbonate Excess	Abnormal	0.24	1.48 [0.76, 2.87]
	Not Taken	0.99	0 [0, Inf]
pH acid/base scale	Abnormal Not Taken	0.13	1.59 [0.87, 2.91] 9.4E06 [0, Inf]
Coinfection	NOC Taken	0.55	3.4200 [0, 1111]
Blood Culture	TRUE	0.99	0 [0, Inf]
Respiratory	TRUE	0.36	2.71 [0.32, 22.69]
Urine	TRUE	0.43	0.45 [0.06, 3.24]
Viral	TRUE	0.02	16.64 [1.7, 162.66]
Diabetes			
Glucose	Abnormal	0.36	1.55 [0.61, 3.92]
	Not Taken	0.60	0.84 [0.44, 1.61]
Full Blood Count Tests			
	Mild	0.05	1.76 [1.01, 3.09]
Hemoglobin	Moderate	0.99	1.01 [0.40, 2.51]
	Severe	0.15	4.62 [0.58, 37.05]
	Not Taken Mild	0.99 <b>0.01</b>	1.3E9 [0, Inf]
	Moderate	0.01	2.8 [1.33, 5.90] 5.81 [1.21, 28.03]
Platelet Count	Severe	0.10	20.44 [0.57, 734.84
	Not Taken	0.99	0 [0, Inf]
	Mild	0.12	1.98 [0.83, 4.73]
1	Moderate	0.23	1.81 [0.69, 4.76]
Lymphocytes	Severe	0.14	2.61 [0.74, 9.22]
	Not Taken	NA	NA
	Mild	0.02	0.05 [4E-3, 0.59]
Neutrophils	Moderate	0.73	0.22 [3.1E-5, 1.4E3]
•	Severe	0.38	1.45 [0.63, 3.32]
	Not Taken Mild	NA 0.82	NA 1.1 [0.48, 2.52]
Neutrophil - Lymphocyte	Moderate	0.82	1.15 [0.39, 3.44]
Ratio	Severe	0.41	1.89 [0.41, 8.69]
	Not Taken	NA	NA
	Mild	0.72	0.83 [0.29, 2.38]
White Cell Count	Moderate	0.73	0.21 [2.5E-5, 1.6E3]
white cell count	Severe	0.83	1.11 [0.43, 2.83]
	Not Taken	NA	NA
Urea & Electrolytes Tests			
C-Reactive Protein	Abnormal	0.07	4.46 [0.91, 21.93]
	Not Taken	0.94	0.90 [0.07, 12.34]
Estimated Glomerular	Abnormal	0.41	0.72 [0.33, 1.58]
Filtration Rate			
	Not Taken	0.04 3.71E-04	0.25 [0.06, 0.95] 2.74 [1.57, 4.77]
Urea	Abnormal Not Taken	0.95	0.94 [0.11, 7.76]
Investigatory Tests	NOL TAKEN	0.55	U.54 [U.11, /./0]
Brain / B-type natriuretic	Abnormal	0.72	1.47 [0.18, 11.76]
peptide	Not Taken	0.81	1.24 [0.21, 7.40]
D-Dimer	Abnormal	0.31	0.42 [0.08, 2.24]
D-Dilliel	Not Taken	0.23	0.37 [0.07, 1.89]
	Mild	0.10	5.65 [0.71, 45.00]
Ferritin	Moderate	0.61	1.52 [0.30, 7.58]
	Severe	0.84	1.30 [0.10, 17.54]
	Not Taken	0.63	1.30 [0.45, 3.72]
Eibringer -	Mild	0.21	11.93 [0.26, 552.59
Fibrinogen	Severe Not Taken	0.42	0.26 [0.01, 6.77]
	Not Taken Mild	0.92	1.07 [0.27, 4.22] 14.88 [0.46, 477.41
	Mild		5.41 [0.20, 145.69]
	Moderate Severe	0.31	4.20 [0.08, 217.62]
Lactate dehydrogenase	307010	0.40	
Lactate dehydrogenase			
Lactate dehydrogenase	Not Taken	0.61	2.13 [0.12, 39.40]
Lactate dehydrogenase  Troponin-T	Not Taken  Abnormal  Not Taken	0.61 0.68 0.58	1.31 [0.37, 4.65] 1.40 [0.43, 4.53]




Figure S9: Model calibration depicting a standard GLM model trained on: (Top) all data and tested on all data (Middle); training data (n=590) and tested on the same; (Bottom) training data and tested on validation data (n=293). A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.




Figure S10: Frequency of LASSO logistic regression variables having a coefficient greater or less than 0. Red and black lines indicate thresholds for 20% and 50% frequency.




Figure S11: Heatmap representation of the LOO variable selection output from Bayesian projective prediction ranking predictive power as a function in change of AUC. The color of an individual cell shows the proportion of times in the LOO process a variable was chosen at that particular rank of predictive strength. Note this demonstrates a reduced 15-biomarker model (51 variables total), where biomarkers that had 'Test Not Taken' ranked as their most important predictive element were removed from the model.

Solution Terms	AUC	Difference	ELPD LOO	Standard Error	Difference	Standard Error
<na></na>	0	-0.8	-358.5	9.7	-61.6	10.7
UreaAbnormal	0.5	-0.3	-326.3	11.4	-29.4	8.3
poctLACNA	0.6	-0.2	-310.6	12.2	-13.6	6.4
O2NA	0.6	-0.2	-310.6	12.2	-13.6	6.4
CO2NA	0.6	-0.2	-310.5	12.1	-13.6	6.3
Age	0.8	0	-302.2	11.9	-5.3	5
PTAbnormal	0.8	0	-299.2	12	-2.2	4.3
NLRSevere	0.8	0	-307.6	12.3	-10.7	4
LDHNA	0.8	0	-304.7	12.5	-7.8	3.7
poctpHAbnormal	0.8	0	-302.3	12.4	-5.4	3.4
LymphocytesSevere	0.8	0	-302.9	12.4	-5.9	3.4
APTTMild	0.8	0	-301.4	12.4	-4.5	3.4
eGFRAbnormal	0.8	0	-299	12.4	-2	3.3
NeutrophilsSevere	0.8	0	-301.8	12.6	-4.8	3.1
APTTModerate	0.8	0	-302.5	12.8	-5.6	3
FERNA	0.8	0	-304.7	12.8	-7.8	2.9
fibNA	0.8	0	-302.4	12.8	-5.4	2.8
CRPAbnormal	0.8	0	-303.1	12.7	-6.2	2.8
CO2Abnormal	0.8	0	-301.2	12.8	-4.3	2.7
DDMAbnormal	0.8	0	-302.4	12.7	-5.5	2.6
HBSevere	0.8	0	-302.9	12.8	-6	2.6

Figure S12: Summary statistics of Bayesian projective prediction ranking the contribution of each variable by change in AUC and expected log-predictive density (ELPD)

Biomarker	Binary Categorical Variable	Bayesian Horshoe Odds Ratios CI [2.5%, 97.5%]	Projective Prediction 3-Biomarker Mode Odds Ratios CI [2.5%, 97.5%]
Demographics / Other			
Age	-	1.03 [1.02, 1.05]	1.02 [1, 1.03]
Gender	Female	0.99 [0.74, 1.3]	
Blood Clotting Tests	Mild	1.57 [0.87, 4.63]	1
Activated partial	Moderate	3.24 [0.81, 112.13]	
thromboplastin time	Not Taken	0.93 [0.55, 1.32]	
Dunth annahin Tima	Abnormal	1.66 [0.91, 4.18]	2.32 [1.15, 4.61]
Prothrombin Time	Not Taken	0.99 [0.64, 1.55]	0.63 [0.41, 0.9]
Blood Gas Tests			
Carbon Dioxide	Abnormal	1.05 [0.69, 1.81]	
	Not Taken Abnormal	0.64 [0.13, 1.6]	
Lactate	Not Taken	0.89 [0.36, 1.53]	
	Abnormal	0.63 [0.13, 1.58] 1.1 [0.66, 2.52]	
Oxygen	Not Taken	0.63 [0.13, 1.56]	
Diambarata France	Abnormal	1.13 [0.84, 1.91]	
Bicarbonate Excess	Not Taken	1.1 [0.68, 2.17]	
pH acid/base scale	Abnormal	1.3 [0.91, 2.31]	
	Not Taken	1.17 [0.78, 2.54]	
Coinfection		0.0000000000000000000000000000000000000	
Blood Culture	TRUE TRUE	0.6 [0.04, 1.4]	
Respiratory Urine	TRUE	1.1 [0.56, 3.19] 0.94 [0.39, 1.72]	
Viral	TRUE	1.81 [0.77, 14.79]	
Diabetes		[0.,7,14.79]	
	Abnormal	1.1 [0.76, 2.01]	1
Glucose	Not Taken	0.96 [0.66, 1.3]	
Full Blood Count Tests			
	Mild	1.11 [0.85, 1.7]	
Hemoglobin	Moderate	1 [0.63, 1.54]	
	Severe	1.57 [0.77, 8.07]	
	Not Taken Mild	1.3 [0.55, 8.27]	
	Moderate	1.35 [0.89, 2.83] 1.58 [0.83, 6.12]	
Platelet Count	Severe	1.41 [0.64, 11.32]	
	Not Taken	0.97 [0.34, 2.29]	
	Mild	1.05 [0.76, 1.6]	
Lymphocytes	Moderate	1.02 [0.75, 1.48]	
Lymphocytes	Severe	1.2 [0.84, 2.35]	
	Not Taken	1.31 [0.56, 8.86]	
	Mild Moderate	0.66 [0.13, 1.27] 1 [0.33, 2.96]	
Neutrophils	Severe	1.14 [0.82, 1.95]	
	Not Taken	1.31 [0.57, 8.9]	
	Mild	1.04 [0.77, 1.55]	1.32 [0.92, 2.29]
Neutrophil - Lymphocyte	Moderate	1.08 [0.79, 1.78]	1.98 [1.34, 3.38]
Ratio	Severe	1.38 [0.86, 3.41]	2.55 [1.5, 5.34]
	Not Taken	1.31 [0.57, 8.84]	3.22 [0.94, 14.32]
	Mild	0.91 [0.48, 1.35]	
White Cell Count	Moderate Severe	1.04 [0.37, 3.61] 1.12 [0.78, 2]	
	Not Taken	1.29 [.055, 8.15]	
Urea & Electrolytes Tests	TORCH		
	Abnormal	2.04 [0.93, 7.61]	1
C-Reactive Protein	Not Taken	1.11 [0.55, 3.54]	1
Estimated Classes			
Estimated Glomerular Filtration Rate	Abnormal	1.03 [0.71, 1.6]	
ation nate	Not Taken	0.72 [0.26, 1.16]	
Urea	Abnormal	2.83 [1.72, 4.65]	3.28 [2.2, 5.2]
	Not Taken	1.07 [0.56, 2.53]	0.84 [0.25, 1.81]
Investigatory Tests		I	ı
Brain / B-type natriuretic	Abnormal	1.05 [0.64, 1.99]	1
peptide	Not Taken	0.95 [0.53, 1.49]	<del> </del>
D. Di	Abnormal	1.07 [0.66, 2.08]	
D-Dimer	Not Taken	0.85 [0.4, 1.3]	
	Mild	1.43 [0.75, 6.87]	
Ferritin	Moderate	1.07 [0.65, 2.14]	<b></b>
	Severe Not Taken	1.01 [0.44, 2.35]	-
	Not Taken Mild	0.93 [0.56, 1.34] 1.32 [0.61, 8.49]	
Fibrinogen	Severe	0.92 [0.26, 2.21]	
ormogen	Not Taken	0.92 [0.26, 2.21]	
	Mild	1.29 [0.7, 5.43]	
	Moderate	1.07 [0.56, 2.51]	1
Lactate dehydrogenase	Severe	1.05 [0.47, 2.96]	<u></u>
	Not Taken	0.71 [0.24, 1.22]	
	NOL TAKEN	0.71 [0.24, 1.22]	
	Abnormal	1.01 [0.68, 1.55]	
Troponin-T			-
	Not Taken	1.02 [0.71 ,1.57]	
Intercept			

Figure S13: Odds ratios for full Bayesian model and geduced 3-biomarker model via projective prediction




Figure S14: Model calibration depicting Projective Prediction 3-biomarker model tested on: (Top) training data (n=590); (Bottom) validation data (n=293). Note the models do not have points for each of the 10 probability bins because some ranges, e.g. 0.9-1.0 had no patients in this band as judged by the model output. A well calibrated model should evenly distribute outcome probabilities, i.e. be close to unity.